PDL BioPharma (PDLI) Reports 4Q Earnings: It’s a Miss

PDL BioPharma, Inc. (PDLI) reported fourth quarter non-GAAP EPS of $0.32 after the close Monday, compared to the consensus estimate of $0.57. Revenues increased 4.5% from last year to $117.1 million. Analysts expected revenues of $158.15 million. The stock is now down $0.46 to $6.88 on 3.5 million shares.

For full year 2014, total revenues increased 27% to $581.2 million from $456.3 million in 2013. Operating expenses came in at $34.9 million, compared with $29.8 million in 2013.

On valuation measures, PDL BioPharma Inc. shares, which currently have an average 3-month trading volume of 2.6 million shares, trade at a trailing-12 P/E of 3.72, a forward P/E of 3.45 and a P/E to growth ratio of 0.25. The median Wall Street price target on the name is $8.00 with a high target of $9.00. Currently ticker has  no ‘Buy’ endorsements, compared to 2 ’Holds’ and no ‘Sell’.

Profitability-wise, PDLI has a t-12 profit and operating margin of 70.48% and 93.41%, respectively. The $1.18 billion market cap company reported $293.7 million in cash vs. $492.90 million in debt in its most recent quarter.

PDLI currently prints a one year loss of about 11%, and a year-to-date loss of around 6%.

The chart below shows where the equity has traded over the last 12 months.

PDL BioPharma, Inc. manages a portfolio of patents and royalty assets. The company was founded in 1986 and is headquartered in Incline Village, Nevada.

Create Content With AI

Try TradingView For Free

Risk Our Money Not Yours | Get 50% Off Any Account

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.